The Effect of Paricalcitol and Calcitriol with or without Calcimimetics on Pulse Wave Velocity and Serum Levels for Parathyroid Hormone, Calcium and Phosphorus in Maintenance Hemodialysis Patients

• Published in: Acta endocrinologica (Bucharest, Romania : 2005) Vol. 19; no. 4; pp. 480 - 486
• Main Author: Bal, A
• Format: Journal Article
• Language: English
• Published: Romania The Publishing House of the Romanian Academy 01.10.2023
• Subjects: Endocrine Care; pulse wavw velocity; hemodialysis; paricalcitol; calcitriol
• ISSN: 1841-0987; 1843-066X
• DOI: 10.4183/aeb.2023.480

Different vitamin D analogs might have advantages over calcitriol. To evaluate the effects of paricalcitol . calcitriol based vitamin D receptor activators on calcium-phosphate metabolism and pulse wave velocity in hemodialysis patients. Observational, cross-sectional and 1 year follow-up study. 181 hemodialysis patients were enrolled in this study as divided in to 5 groups based on vitamin D therapy. Baseline and 12 month data on blood biochemistry, pulse wave velocity and cumulative dose of treatments were compared in each study group as well as in overall paricalcitol . calcitriol-based treatment groups. From baseline to 12 month, significant improvement in pulse wave velocity and parathyroid hormone was shown in paricalcitol-based treatment group without a significant change in calcium, phosphate, alkaline phosphatase. A significant increase in pulse wave velocity, serum phosphate levels, calcium x phosphate product and serum alkaline phosphatase levels were noted in calcitriol-based treatment group with no significant change in serum calcium and parathyroid hormone levels. Our findings revealed superiority of paricalcitol than calcitriol based vitamin D receptor activator therapy in terms of serum phosphate levels, CaxP product, dose requirement for vitamin D and the control of pulse wave velocity.